Pelthos Therapeutics Inc. Company Profile

Background

Pelthos Therapeutics Inc. is a biopharmaceutical company dedicated to commercializing innovative, safe, and efficacious therapeutic products to address unmet medical needs. The company's mission is to improve patient outcomes by developing and delivering novel treatments for conditions lacking effective therapies. Pelthos operates within the pharmaceutical industry, focusing on dermatological and pain management solutions.

Key Strategic Focus

Pelthos's strategic focus centers on the commercialization of ZELSUVMI™ (berdazimer) topical gel, 10.3%, the first FDA-approved prescription medication for molluscum contagiosum that can be administered at home. Additionally, the company is advancing its NaV 1.7 development programs targeting various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Pelthos leverages its proprietary NITRICIL™ technology platform to develop these innovative treatments.

Financials and Funding

In July 2025, Pelthos completed a merger with Channel Therapeutics Corporation and secured a $50.1 million private placement from strategic investors led by Murchinson Ltd. This funding includes the conversion of approximately $18.8 million in bridge capital provided earlier in 2025. The capital is intended to support the commercial launch of ZELSUVMI™ and further development of the company's pipeline.

Pipeline Development

Pelthos's lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3%, received FDA approval in 2024 for the treatment of molluscum contagiosum in adults and pediatric patients aged one year and older. The company plans to launch ZELSUVMI™ in July 2025. Additionally, Pelthos is evaluating its NaV 1.7 development programs for treating various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.

Technological Platform and Innovation

Pelthos's proprietary NITRICIL™ technology platform facilitates the controlled release of nitric oxide, enabling the development of topical treatments for various conditions. This platform underpins the development of ZELSUVMI™ and other pipeline candidates, offering a novel approach to treating dermatological and pain-related conditions.

Leadership Team

Scott M. Plesha, Chief Executive Officer: With over 30 years in the pharmaceutical industry, Mr. Plesha has extensive experience in building and leading specialty pharma commercial organizations. Prior to joining Pelthos in November 2023, he served as President and Chief Commercial Officer at BioDelivery Sciences, where he significantly grew the company's sales.

Frank Knuettel II, Chief Financial Officer: Mr. Knuettel has a strong background in financial leadership within early-stage public companies. Before becoming CFO of Pelthos, he was CEO of Channel Therapeutics Corporation and has held various executive roles, including CFO positions at Unrivaled Brands and Marathon Patent Group.

Sai Rangarao, MBA, Chief Commercial Officer: Mr. Rangarao joined Pelthos in March 2024, bringing over a decade of experience in leading and marketing pharmaceutical products. He previously held leadership roles at Collegium Pharmaceutical and BioDelivery Sciences International, where he contributed to significant market share growth.

Carri Geer, PhD, Senior Vice President, Chief Technology Officer: Dr. Geer leads the NITRICIL™ technology platform and related product development. She has over 20 years of experience with nitric oxide and pharmaceutical product development, previously serving as CTO for Novan, Inc.

Melvin Whitehead, Senior Vice President, Manufacturing Operations: Mr. Whitehead oversees manufacturing and supply chain operations at Pelthos, bringing over 25 years of industry experience across various product modalities and dosage forms.

John M. Gay, CPA, Senior Vice President, Finance & Accounting: Mr. Gay has 25 years of experience in public company finance and accounting, previously serving as CFO of LNHC, Inc. and holding leadership roles at Novan and Furiex Pharmaceuticals.

Suzie Paulson, Vice President of Human Resources: Ms. Paulson leads Pelthos's HR strategy and operations, with over two decades of experience in the pharmaceutical industry, including significant roles at BioCryst Pharmaceuticals and Salix Pharmaceuticals.

Matt Rysavy, Vice President of Market Access and Trade: Mr. Rysavy joined Pelthos in April 2025, bringing over 25 years of pharmaceutical industry experience, with a focus on market access roles. He previously held leadership positions at Verona Pharma and BioDelivery Sciences International.

Leadership Changes

In July 2025, following the merger with Channel Therapeutics Corporation, Frank Knuettel II transitioned from CEO of Channel to Chief Financial Officer of Pelthos. This strategic appointment aims to leverage Mr. Knuettel's financial expertise to support Pelthos's growth and commercialization efforts.

Competitor Profile

Market Insights and Dynamics

The market for molluscum contagiosum treatments is significant, with an estimated 16.7 million individuals affected in the United States. The approval and launch of ZELSUVMI™ address a substantial unmet need, offering a convenient at-home treatment option for patients.

Competitor Analysis

Pelthos's primary competitors include companies developing treatments for dermatological conditions and chronic pain management. While specific competitors are not detailed in the available information, Pelthos's focus on innovative, at-home therapies positions it uniquely in the market.

Strategic Collaborations and Partnerships

Pelthos has established significant collaborations to strengthen its market position:

Ligand Pharmaceuticals: Ligand invested $18 million in Pelthos and is entitled to a 13% royalty on worldwide net sales of ZELSUVMI™, highlighting a strategic partnership to support the product's commercialization.

Murchinson Ltd.: Led a group of strategic investors in a $50.1 million private placement, providing essential capital for Pelthos's operations and product launch.

Operational Insights

Pelthos's strategic considerations include:

Market Position: By offering the first FDA-approved at-home treatment for molluscum contagiosum, Pelthos differentiates itself from competitors relying on in-office procedures.

Competitive Advantages: The proprietary NITRICIL™ technology platform enables the development of novel therapies with controlled nitric oxide release, providing a unique approach to treatment.

Strategic Opportunities and Future Directions

Pelthos's strategic roadmap includes:

ZELSUVMI™ Launch: Successfully launching and commercializing ZELSUVMI™ in July 2025 to establish a strong market presence.

Pipeline Expansion: Advancing NaV 1.7 development programs to address various pain conditions, potentially expanding the company's therapeutic offerings.